⁶⁸Ga-DPA in the Lung Cancer Diagnosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: 68Ga-DPA PET/CT.
- Who it may be relevant to
- Registry conditions: Lung Cancers. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Application of PD-L1 Targeted Imaging Agent ⁶⁸Ga-DPA in the Diagnosis of Lung Cancer
Overview
In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile and excellent imaging performance. Leveraging the established strengths of the Department of Nuclear Medicine at Peking Union Medical College Hospital, we now plan to conduct an exploratory PET/CT imaging study in lung cancer patients. This study aims to provide an in vivo, non-invasive, and visualizable technique for detecting PD-L1 expression levels and spatial distribution in tumors. It will further validate the clinical utility of this technology, offering critical diagnostic insights for initial assessment and treatment efficacy evaluation in PD-L1-positive tumor patients undergoing PD-L1-targeted therapies.
Interventions
- Diagnostic test 68Ga-DPA PET/CT
Use 68Ga-DPA PET/CT in the diagnosis of lung cancer
Primary outcome measures
- SUV [Time frame: 0-180 minutes post-injection]
Eligibility criteria
Inclusion criteria
- Age ≥18 years, regardless of gender.
- Patients clinically confirmed or suspected of lung cancer, with pathological specimens obtainable via biopsy or surgery within the recent 2 months.
- At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Expected survival >3 months.
Exclusion criteria
- Severe hepatic or renal dysfunction (serum creatinine >3.0 mg/dL or any liver enzyme level ≥5× upper limit of normal).
- Women who are planning pregnancy, pregnant, or breastfeeding.
- Inability to lie supine for 30 minutes.
- Claustrophobia or other psychiatric disorders.
- Intolerance to any clinical procedures in the study.
- Other conditions deemed ineligible by the investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- 100730 — Beijing
Identifiers
NCT: NCT07023068 · PUMCH-PDL1